Tessera Therapeutics is pioneering Gene Writing technology to develop genetic medicines that can precisely write therapeutic messages into the genome. The company's platform combines novel molecular machinery with computational design to address genetic diseases that have been difficult to treat with existing gene therapy approaches. Founded by leading scientists from MIT and Harvard, Tessera aims to expand the reach of genetic medicine beyond rare diseases to more common conditions. The company has raised significant funding to advance its gene writing platform and build a pipeline of therapeutic programs.
Tessera Therapeutics has received investment from 1 venture capital firm.
Gene writing company developing a new class of genetic medicines that can write therapeutic messages into the genome to treat or cure diseases.
Tessera Therapeutics has received investment from Flagship Pioneering. These venture capital firms and investors provide both capital and strategic support.
Tessera Therapeutics has raised $300M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
Tessera Therapeutics was founded in 2018 and is headquartered in Cambridge, MA.
Tessera Therapeutics operates in the Biotech sector. Gene writing company developing a new class of genetic medicines that can write therapeutic messages into the genome to treat or cure diseases.
